136137-86-5

Usage

Structure

Chiral compound with two stereocenters

Usage

Organic Synthesis: Versatile intermediate, especially in pharmaceutical industry
Pharmaceuticals: Potential applications in drug production and synthesis of biologically active molecules
Material Sciences: Possible uses in material sciences
Catalysis: Potential application as a catalyst

Upstream product

• 87-69-4 L-Tartaric acid 
• 100-46-9 benzylamine 
• 75172-31-5 (3R,4R)-1-benzyl-3,4-dihydroxypyrrolidine-2,5-dione 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 136137-85-4 (3R,4R)-1-benzyl-2,5-dioxopyrrolidine-3,4-diyl diacetate 

Downstream Products

• 162466-21-9 (2S,3S,4S)-1-Benzyl-2-methyl-pyrrolidine-3,4-diol 
• 502841-31-8 (2S,3S,4S)-1-Benzyl-2-isopropyl-pyrrolidine-3,4-diol 
• 502841-32-9 (2S,3S,4S)-1-Benzyl-2-phenyl-pyrrolidine-3,4-diol 
• 502841-30-7 (2S,3S,4S)-1,2-Dibenzyl-pyrrolidine-3,4-diol 
• 502841-26-1 (2S,3S,4S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-2-methyl-pyrrolidine 
• 502841-28-3 (2S,3S,4S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-2-isopropyl-pyrrolidine 
• 502841-22-7 (3R,4S,5S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-5-methyl-pyrrolidin-2-one 
• 502841-24-9 (3R,4S,5S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-5-isopropyl-pyrrolidin-2-one 
• 502841-29-4 (2S,3S,4S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-2-phenyl-pyrrolidine 
• 502841-25-0 (3R,4S,5S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-5-phenyl-pyrrolidin-2-one 

Relevant academic research and scientific papers

Unexpected rearrangements of rhodium carbenoids containing a pyrrolidin-1-yl group

Ketone- and ester-substituted diazo compounds, which contain a pyrrolidine moiety were treated with dirhodium tetraacetate generating the corresponding rhodium carbenoids. They were expected to insert into a CH bond of the pyrrolidine moiety but reacted differently. The ketone-substituted rhodium carbenoid underwent a Wolff rearrangement. The resulting ketene continued to react by lactamization and electrocyclic ring-opening and gave an acrylamide. The ester-substituted rhodium carbenoid underwent a [1.2]-shift of the (pyrrolidin-1-yl)methyl moiety, which resulted in a methacrylic ester. For each rearrangement a mechanism is suggested.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

Disclosed are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also disclosed are pharmaceutical compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.

Synthesis of pyrrolidine based natural or unnatural product derivatives (1): Application of efficient asymmetric induction of C-2 position in polysubstituted pyrrolidines

A novel method for synthesis of polysubstituted pyrrolidines, which possess a C-2 stereocenter, was developed. The strategy involves Grignard addition to the succinimide, derived from L-tartaric acid, followed by stereocontrolled triethylsilane promoted reduction of the resulting cyclic amidols.

A Practical and Divergent Way to Trihydroxylated Pyrrolidine Derivatives as Potential Glycosidase Inhibitors via Stereoselective Intermolecular cis-Amidoalkylations

A practical and divergent way from the common tartrimide 1 to trihydroxylated pyrrolidines 2a-h as potential glycosidase inhibitors has been developed. cis-Amidoalkylations on the acyliminium intermediate 5 of the corresponding TBS-protected tartaric imid

Chiral cyclic imides with c2-symmetry. Novel reagents for the synthesis of optically pure lactones containing three contiguous tertiary centers

Asymmetric reactions employing C2-symmetrical imides readily prepared from L-tartaric acid with Grignard reagents and sodium borohydride afforded a separable mixture of two hydroxyamides with high diastereoselectivity. Products were lactonized